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The structural characteristics of mesoionic compounds, which contain distinct regions of positive and negative charges associated with
a poly-heteroatomic system, enable them to cross cellular membranes and interact strongly with biomolecules. Potential biological
applications have been described for mesoionic compounds. 1,3,4-Thiadiazolium mesoionic compound (MI-D), a new mesoionic
compound, has been demonstrated to be extremely cytotoxic to B16-F10 murine melanoma cells when compared to fotemustine
and dacarbazine, drugs of reference in melanoma treatment protocols, describing inhibition of tumours grown in vitro and in vivo.W e
now evaluate the effects of mesoionic compound MI-D on different human melanoma cell lines. The drug decreased the viability and
proliferation of MEL-85, SK-MEL, A2058 and MEWO cell lines in vitro, showing a considerable cytotoxic activity on these human cells.
Adhesion of MEL-85 cells was evaluated in the presence of the drug using different extracellular matrix (ECM) constituents. MI-D
decreased MEL-85 adhesion to laminin, fibronectin and matrigel. The morphology and actin cytoskeleton organisation of MEL-85 cells
were also modified on MI-D treatment. These results on human melanoma cell lines indicate that MI-D is a very encouraging drug
against melanoma, a tumour that is extremely resistant to chemotherapy.
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Compounds of the mesoionic class have interesting structural
features provided by their betaine-like character. They consist of a
five-membered heterocyclic ring associated with a sextet of p and p
electrons, supporting a partial positive charge in the heterocyclic
ring, which is counterbalanced by a formal negative charge on the
atom of the a-side chain (Ollis and Ramsden, 1976; Newton and
Ramsden, 1982; Cheung et al, 1992). The association of these
characteristics suggests a high probability of strong interactions
with biomolecules such as DNA and/or proteins. Although
mesoionic compounds are internally charged, they are neutral
overall, and can therefore cross biological membranes in vivo (Kier
and Roche, 1967).
All the different classes of mesoionic compounds (sydnones,
sydnonimines, isosydnones and 1,3,4-thiadiazoles) have received
considerable attention and have been extensively studied because
of their unique structures, reaction behaviour, biological activities
and possible pharmaceutical use (Moustafa and Eisa, 1991; Corell
et al, 1994; Rehse et al, 1995; Satyanarayana and Rao, 1995). These
include anti-inflammatory, analgesic, antibacterial, antifungal and
antitumour activities (Badachikar et al, 1986; Shinzato et al, 1989;
Moustafa and Eisa, 1991; Grynberg et al, 1992; Montanari et al,
1992; Satyanarayana and Rao, 1995; Grynberg et al, 1997; Senff-
Ribeiro et al, 2003, 2004). Potent antiplatelet, fibrinolytic,
thrombolytic and broncholytic effects (Corell et al, 1994;
Kankaanranta et al, 1996), and effects on the cardiovascular
system (Majid et al, 1980; Rudolph and Derschinger, 1991; Rehse
and Konig, 1995; Rehse et al, 1995) have also been described for
mesoionic compounds. Some effects described for these com-
pounds are intimately related to the presence of specific
substituent groups on the ring (Corell et al, 1994; Satyanarayana
and Rao, 1995; Kankaanranta et al, 1996; Grynberg et al, 1997), or
to the ability to release nitric oxide from their molecular structures
(Hogg et al, 1992).
A new mesoionic compound, 4-phenyl-5-(4-nitrocinnamoyl)-
1,3,4-thiadiazolium-2-phenylamine chloride (MI-D) was synthesised
by Grynberg et al (1997) (Figure 1), for which it was shown
the enhancement of the survival of Ehrlich carcinoma and Sar-
coma-180 tumour-bearing mice, preventing tumour growth, with
no significant concomitant alterations in the haematologi-
cal parameters of tested animals, at a dose of 25mgkg
 1
(57mmolkg
 1).
MI-D was shown to be able to inhibit the respiratory chain
between complexes II and III, collapse the transmembrane
potential, and stimulate ATPase activity in intact mitochondria
(Cadena et al, 1998). Alterations were also reported in membrane
permeability and fluidity, which are related to its effect on the
energy-linked functions of mitochondria (Cadena et al, 2002).
Recent studies in our laboratory evaluating a series of 1,3,4-
thiadiazolium mesoionics showed that MI-D, which has an NO2
substituent on the cinnamoyl ring, was the most effective against
the melanoma murine model B16-F10 (Senff-Ribeiro et al, 2004).
Compared with two other antineoplastic agents (fotemustine and
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ydacarbazine), it was effective against the murine model both in
vitro and in vivo, under the same experimental conditions and
with the same molar concentrations (Senff-Ribeiro et al, 2003).
Although antitumour effects against Ehrlich and Sarcoma-180
tumour models, and even against the aggressive melanoma murine
model B16-F10, have already been demonstrated for MI-D
(Grynberg et al, 1997; Senff-Ribeiro et al, 2003, 2004), it has not
been tested against human melanoma cell lines.
We now study the effects of MI-D on four established human
melanoma cell lines: MEL-85, SK-MEL, A2058 and MEWO. The in
vitro viabilities and proliferations of these cell lines in the presence
of MI-D were evaluated. In order to obtain further insights
concerning MI-D’s anti-melanoma activity, cell features of
adhesion, morphology and actin cytoskeleton organisation, which
are deeply related to the development and establishment of
tumours, were also subjects studied using the MEL-85 cell line.
MATERIALS AND METHODS
Materials
MI-D (4-phenyl-5-(4-nitro-cinnamoyl)-1,3,4-thiadiazolium-2-phe-
nylamine chloride) was synthesised in the Department of
Chemistry of the Rural Federal University of Rio de Janeiro,
Brazil, as described elsewhere (Grynberg et al, 1997). Its structure
was confirmed by
1H- and
13C-NMR spectroscopy and mass
spectrometry. Dulbecco’s modified Eagle’s medium (DMEM),
RPMI1640 medium and fetal bovine serum (FBS) were obtained
from Cultilab (Campinas, Brazil); penicillin and gentamycin were
both purchased from GIBCO (Bethesda, USA). Paraformaldehyde
(20%, aqueous solution) was from EMS (Electron Microscopy
Sciences, Washington, USA). Phalloidin labelled with FITC was
from Molecular Probes (Eugene, USA) and the aqueous mounting
medium, Fluormount-G
s from EMS (Washington, USA). Trypan
blue, MTT, crystal violet and glycine were obtained from Sigma
Aldrich (St Louis, USA). DMSO was from Merck. All other reagents
were commercial products of the highest available purity grade.
Drug solutions
MI-D was dissolved in dimethylsulphoxide (DMSO) for its
experimental use. In order to minimise solvent interference,
several stock solutions of MI-D were prepared so that at the
desired final concentrations of MI-D in the assays, the amounts of
DMSO were identical and equal to 0.12%.
Cell lines and culture conditions
Human melanoma cell lines used in this study were kindly
provided by the Ludwig Institute for Cancer Research (Sa ˜o Paulo,
Brazil). Cells were maintained in liquid nitrogen with a low
number of passages. After thawing, the cells were grown in
monolayer cultures in the appropriate media containing penicillin
(100Uml
 1) and gentamicin (50mgml
 1). MEL-85 and MEWO
cells were cultured in RPMI containing 10% FBS, SK-MEL cells in
RPMI containing 15% FBS and A2058 cells in DMEM containing
10% FBS. The cultures were kept at 371C under a humidified
atmosphere plus 5% CO2. Release of cells was performed by a
treatment for a few minutes with a 2mM solution of ethylenedia-
minetetraacetic acid (EDTA) in phosphate-buffered saline (PBS).
After being counted, cells were then resuspended in an adequate
volume of the respective medium supplemented with FBS and
again plated in the presence or absence of MI-D.
Cell viability assay
Viability assays were carried out on 24-well plates (TPP,
Trasadingen, Switzerland). Human melanoma cells
(5 10
5cellswell
 1) were plated and allowed to adhere and grown
for 20h before incubation with the drug. MI-D was added in
varying concentrations up to 75mM. At each determined interval
(24 and 48h), supernatants and cells were harvested, centrifuged,
washed with PBS and the viability was measured by the Trypan
blue-exclusion assay (Phillips, 1973). Briefly, Trypan blue (0.4% in
PBS, pH 7.4) was added to the cell suspension and the number of
viable (unstained) and nonviable (stained) cells was counted using
a Neubauer Chamber. For control experiments, the appropriate
medium contained adequate amounts of vehicle (0.12% of DMSO).
Cell viability of controls was normalised to 100%.
Cell proliferation assay
Human melanoma cells (6 10
3cellswell
 1) were grown for 16h on
96-well plates (TPP) containing an appropriate medium supple-
mented with an adequate amount of FBS. The medium was then
replaced by a serum-free one. After 24h, this was replaced with the
respective medium containing the usual concentrations of FBS plus
MI-D, at different concentrations (2.5–25mM) in quadruplicate.
Controls consisted of the respective medium alone or in the
presence of 0.12% DMSO, which was the MI-D solvent. After 24, 48
and 72h the number of cells in each well was determined using the
MTT method (Mosmann, 1983). MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide] was dissolved in Hanks’
balanced saline solution (HBSS) at 5mgml
 1. At the above
intervals, 20ml of the MTT solution were added to each well and
the plates were incubated at 371Cf o r3 h .T h eM T Ts o l u t i o nw a s
removed and DMSO was added and mixed thoroughly to dissolve
the dark-blue crystals. The plates were then read using a Microelisa
Reader (Bio-Rad, Madison, USA) at 550nm for sample and 655nm
for reference. Results are expressed as the cell number, which was
determined using a standard curve of cells against absorbance.
Cell adhesion assay
Native fibronectin was purified from fresh human plasma
according to the procedure of Engvall and Ruoslahti (1977).
Laminin and matrigel, a reconstituted basement membrane, were
purified from a Engelbreth–Holm–Swarm (EHS) tumour as
described by Paulsson et al (1987) and Kleinman et al (1986),
respectively. The presence and purity of proteins were assessed by
both an electrophoretic analysis on sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE) and Western
blot. Adhesion assays were performed as described by Saiki et al
(1989) with some modifications. Briefly, MEL-85 cells (4 10
4)
with or without MI-D (0.5, 1.0, 2.5 and 5.0mM) were added to
microculture wells (96-well plates, TPP) precoated with fibronec-
tin, laminin or matrigel (10mgml
 1) and blocked with bovine
serum albumin (BSA) 1%. The cultures were incubated at 371C for
N
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N
H
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Cl −
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Figure 1 Chemical structure of 4-phenyl-5-(4-nitrocinnamoyl)-1,3,4-
thiadiazolium-2-phenylamine chloride (MI-D).
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y2h. The wells were washed twice with warm PBS to remove
unattached cells, and then the attached cells were fixed with
methanol and stained with 0.8% crystal violet dissolved in 20%
ethanol. After extensive washing with PBS, the dye was eluted with
50% ethanol in 0.05 M sodium citrate and the absorbance was
measured at 550nm using a MicroElisa Reader (BioRad). At the
end of the experiment, the plates were photographed (Leica-
MPS30) using an inverted microscope (Leica-DMIL). The control
contained the same amount of DMSO as the tested wells (0.12% of
DMSO) and its cellular adhesion was normalised to 100%.
Cell morphology analysis
MEL-85 cells were cultured on glass coverslides for 16h at 371C
under a humidified atmosphere plus 5% CO2. Cells were treated
with 25 and 50mM MI-D for 2h. After treatment, they were washed
twice with PBS and fixed with 2% paraformaldehyde in PBS for
30min at 41C. For the control, the appropriate medium contained
adequate amounts of vehicle (0.12% of DMSO). Coverslides were
stained by Giemsa and studied by bright-field microscopy
(Olympus BX40). Images were acquired ( 400) in grayscale using
a software Image-Plus 4.0 version (Media Cybernetics, Silver
Spring, USA). A morphometric analysis was performed using an
ImageTool software 3.00 version (University of Texas Health
Science Center in San Antonio, USA). Cell features, such as area,
elongation and roundness of about 400 cells were analysed. For
analysis, the area of the object, measured as the number of pixels in
the polygon was converted to percent. Elongation was measured as
the ratio of the length of the major axis to the length of the minor
axis. The result was a value of between 0 and 1 that was converted
to % for analysis to obtain an analytical value. Roundness was
computed as: (4p area)/perimeter
2. The result gave a value of
between 0 and 1 that was converted to % for analysis.
Immunofluorescence microscopy
MEL-85 cells (5 10
4) were plated on glass coverslides (13mm
diameter), which were prepared for confocal immunofluorescence
microscopy. After 16h, MEL-85 cells were incubated with 50mM
MI-D for 2h at 371C under a humidified atmosphere plus 5% CO2.
In the control, the appropriate medium contained adequate
amounts of vehicle (0.12% of DMSO). Cells were washed twice
with PBS and fixed with 2% paraformaldehyde in PBS for 30min at
41C. Cells on coverslides were incubated with 0.1 M glycine for
3min, washed with PBS and then blocked with PBS containing 1%
BSA for 30min at room temperature (251C). After washing thrice
with PBS, coverslides were incubated with phalloidine conjugated
with fluorescein isothiocyanate (FITC) (Molecular Probes) diluted
in PBS (1:200) for 20min. After washing with PBS (10 ) and
once in water, slides were mounted with Fluormont-G
s. Cells were
observed using a confocal fluorescence microscope (Confocal
Radiance 2100, Bio-Rad) coupled to a Nikon Eclipse 800 with plan
apochromatic objectives (Science and Technologies Group Instru-
ments Division, Melville, USA). Images were acquired ( 600)
using Radiance 2100 (Bio-Rad).
Statistical analysis
Statistical analysis of data were carried out using analysis of
variance (ANOVA) and the Tukey test for average comparison.
Mean7s.d. values were used. Significance was defined as Po0.05.
RESULTS
Effect of MI-D on cell viability
Figure 2 shows the effect of the mesoionic compound on the
viability of human melanoma cell lines evaluated 24 and 48h after
treatment with different concentrations of MI-D (2.5–75mM).
Time- and dose-dependent effects were shown by MI-D on the four
cell lines studied.
The viability of MEL-85 cells was reduced to 56% after a 24h
treatment with 10mM MI-D (Figure 2A). At this time of incubation,
75mM MI-D diminished the viability by B82%. When a treatment
of 48h was used, the maximum cytotoxic effect (100%) was
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Figure 2 Effects of MI-D on the viability of different human melanoma cell lines. (A) Effects of MI-D on MEL-85 cells. (B) Effects of MI-D on SK-MEL cells.
(C) Effects of MI-D on A2058 cells. (D) Effects of MI-D on MEWO cells. The viability of melanoma cells was measured at indicated intervals and
concentrations of MI-D using the trypan blue-exclusion assay (n¼4). Values given are the mean7s.d. *Po0.001.
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number of viable cells to 27% after 48h incubation.
SK-MEL cells also had their viability diminished by MI-D
treatment (Figure 2B). After 24h, 25mM MI-D reduced the viability
to B30% and at 50mM to 17%. When the concentration was raised
to 75mM, there were no viable cells after 24h incubation. A volume
of 10mM MI-D reduced the viability to 30% after 48h. At this time,
there was more than 90% of cell death using 50mM MI-D.
The viability of A2058 cells was decreased to B30% when the
concentration of MI-D was 10mM and the incubation time was 24h
(Figure 2C). At this time, the concentrations of 25 and 50mM
reduced the number of viable cells to 12 and 7%, respectively.
When a 48h incubation was assayed, 10mM MI-D reduced the
viability to 20% and 25mM almost gave a maximum cytotoxic effect
(97%). At this time, all A2058 cells were dead when the
concentration of MI-D was 50mM.
MEWO cells were also very sensitive to the toxic effects of MI-D
(Figure 2D). After 24h, MI-D at 10 and 25mM concentrations,
diminished the viability to 23 and 8%, respectively. Increasing the
drug concentration to 75mM resulted in only B1% of viable cells
after 24h. When a 48h treatment was performed, 10mM MI-D
reduced the number of viable cells to 13% while 50mM gave rise to
B100% cell death.
Effect of MI-D on cell growth
Evaluation of the effect of MI-D on the growth of human
melanoma cell lines was performed using a growth–time kinetic
study of up to 72h (Figure 3). Proliferation of all melanoma cell
lines was greatly inhibited by MI-D, even when subcytotoxic
concentrations (1–2.5mM) were tested.
MEL-85 cells (Figure 3A) treated with 5mM MI-D gave a 50%
reduction of cell growth during the 72h experiment. At a
concentration of 10mM, the proliferation of MEL-85 cells was
completely inhibited.
No growth of SK-MEL cells (Figure 3B) was observed when 5mM
MI-D was used. After 24h, 1 and 2.5mM MI-D reduced the number
of cells to B65 and B55%, respectively.
A2058 cells (Figure 3C) had their growth reduced to 55–61%
when the concentration was 2.5mM. When MI-D was used at 5mM,
there was no increase in cell number up to 48h. However, at 72h
there was a recovery and the number of cells increased, being 46%
of the control.
The proliferation of MEWO cells was inhibited by MI-D
(Figure 3D). At a low MI-D dose (2.5mM) a decrease of cell
number of a quarter after 48 and 72h was observed. The
concentration of 5mM allowed cell growth up to 24h, but after
there was no increase in cell number up to 72h. In all, 10mM MI-D
did not allow MEWO growth. It must be pointed out that all cell
lines, when exposed to MI-D at 10mM or more, did not grow and
extensive cell death was observed, confirming the previous data
appearing in Figure 2.
Effect of MI-D on MEL-85 adhesion to laminin, fibronectin
and matrigel
Figure 4 shows the effects of MI-D on MEL-85 adhesion to
extracellular matrix (ECM) constituents, such as laminin, fibro-
nectin and matrigel. Although there were apparent decreases on
cell adhesion when 0.5 and 1mM of MI-D were used, the values
were not statistically different from those of the controls. Higher
concentrations of MI-D significantly inhibited MEL-85 adhesion to
ECM molecules in a concentration-dependent manner. Adhesion
to laminin and fibronectin was decreased to 70 and 55% by 2.5 and
5mM of MI-D, respectively, after 2h exposure (Figures 4A and B).
At 5mM, MI-D diminished MEL-85 adhesion to laminin to B65%
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Figure 3 Effects of MI-D on the proliferation of human melanoma cell lines. (A) Effects of MI-D on MEL-85 cells. (B) Effects of MI-D on SK-MEL cells. (C)
Effects of MI-D on A2058 cells. (D) Effects of MI-D on MEWO cells. The proliferation rates were measured using the MTT method at the times indicated
and at subcytotoxic (2.5mM) and cytotoxic (5–25mM) concentrations (n¼3). Values given are the mean7s.d. *Po0.01 **Po0.001.
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y(Figure 4A) and to fibronectin and matrigel to 34 and 71%,
respectively (Figure 4B and C). The micrographs of the adhesion
on fibronectin (Figure 4D) show that MI-D not only reduced the
number of cells adhering to fibronectin, but also altered the
morphology of MEL-85 cells, which shrinked and became round.
These changes were also observed when cells were assayed for their
adhesion on laminin and matrigel (data not shown).
Effect of MI-D on MEL-85 morphology
Figure 5 shows micrographs of MEL-85 cells stained by Giemsa. It
can be observed with treated cells (Figure 5B and C) that the
presence of MI-D gave rise to a disruption of the interactions
between cells and substratum. MI-D treated cells are not so spread
out as control cells (Figure 5A). The results clearly demonstrate
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Figure 4 Effects of MI-D on the adhesion of MEL-85 human melanoma cell to ECM constituents. (A) MEL-85 adhesion to laminin. (B) MEL-85 adhesion
to fibronectin. (C) MEL-85 adhesion to matrigel. (D) Micrographs of MEL-85 cells adhered to fibronectin. (1) Control cells, (2) cells treated with 2.5mM MI-
D, (3) cells treated with 5mM MI-D. MEL-85 cells (4 10
4) were added to microculture wells precoated with ECM constituents in the presence of indicated
concentrations of MI-D. After a 2h incubation, nonadherent cells were washed and adherent cells were fixed and stained with 0.8% (pv
 1) crystal violet
containing 20% methanol. After extensive washing, the stained cells were lysed with 50% ethanol in 0.05 M sodium citrate and the absorbance was measured
at 550nm. **Po0.01 and ***Po0.001.
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compared to those of the control, as was also observed in adhesion
assays. The treatment with 25mM MI-D gave rise to shrinkage of
some cells, presenting protrusions of the plasma membrane, which
were pinched off to form membrane-enclosed similar apoptotic
bodies probably with cytoplasmic and nuclear contents. Intense
vacuolisation of cytoplasm was observed with treated cells. The
concentration of 50mM affected the morphology of almost all of the
cells. Condensed chromatin masses with intense eosinophilia and
pyknotic nuclei were also observed with treated cells. Morpho-
metric analysis permitted quantification of morphological changes
and showed a reduction of 35% in the area of cells treated with
50mM MI-D. This concentration reduced cell elongation to 56%
and increased cell roundness by 112%.
Effect of MI-D on MEL-85 cytoskeleton organisation
In order to evaluate if the changes on cell shape were due to
alterations on the actin organisation, an experiment using
phalloidin-FITC conjugate was performed (Kusano et al, 2000).
As can be observed in Figure 6, organisation of actin cytoskeleton
was completely disturbed by MI-D treatment. Fluorescence
labelling of MEL-85 cells treated with MI-D did not give rise to
the overall pattern that was observed in control cells, which
showed a considerable organisation of F-actin fibres all over the
cell body. MI-D treatment induced a reorganisation of the F-actin
cytoskeleton architecture. Cells in the presence of MI-D did not
spread and the filamentous structures disassembled or were
reorganised to accumulate in the submembraneous area. Actin
filaments turned into actin granules mainly localised on the edge
of MEL-85 cells. These results point to a disruption of interactions
between cells and the extracellular matrix.
DISCUSSION
We are now able to show that MI-D has considerable cytotoxic and
antiproliferative effects on human melanoma cell lines. These
effects seem to be even more aggressive on human melanoma cells
than those observed with B16-F10 murine melanoma cells (Senff-
Ribeiro et al, 2003, 2004). For example, a dose of 10mM after 48h
incubation, on B16-F10 melanoma cells diminished their viability
to B80% (Senff-Ribeiro et al, 2003, 2004) and in all the four
human melanoma cell lines the viability was lower than 30% under
these conditions. Interestingly, MI-D at a low concentration (5mM),
gave rise to effects of a different magnitude on the viabilities of
A
B
C
Figure 5 Effects of MI-D on the morphology of MEL-85 cells. (A) Micrographs of control cells. (B) Micrographs of MEL-85 cells treated with 25mM MI-D.
(C) Micrographs of MEL-85 cells treated with 50mM MI-D. MEL-85 cells were treated for 2h, fixed and stained with Giemsa. Samples were observed using a
bright-field microscope (Olympus BX40). Closed arrows point to cell shrinkage. Closed arrowheads show vacuolisation of cytoplasm. Open arrows indicate
chromatin condensation. Open arrowheads indicate bleb formation in cell membranes ( 400).
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cell lines (Figure 2A and D) were more sensitive to MI-D than SK-
MEL and A2058 (Figure 2B and C). Inhibitions of different
magnitude on the cell growth of different human melanoma cell
lines were also observed. The concentration of 5mM allowed MEL-
85 growth at a lower rate than that of the control (Figure 3A), but
completely inhibited the growth of SK-MEL cells (Figure 3B). The
results on viability and proliferation are compatible. As one can
observe in Figures 2 and 3, MI-D was very cytotoxic to human
melanoma cells and had also an antiproliferative effect. The
antiproliferative effect of MI-D was present at both noncytotoxic
and cytotoxic doses. The effects of MI-D on the viability and
proliferation of the various human melanoma cell lines show MI-D
to be a toxic drug for human melanoma cells.
Since tumour cell adhesion to ECM constituents is a
fundamental step in tumour development and invasion (Mishima
et al, 1998), we investigated the effect of MI-D on MEL-85
melanoma cells adhesion to laminin, fibronectin and matrigel. Low
MI-D doses were used in order to minimise its extensive metabolic
effects, so that the drug was used at subcytotoxic concentration to
evaluate MEL-85 adhesion to ECM. Overall, 5mM MI-D caused
a slight decrease of B5% on MEL-85 viability after 2h. Under such
an experimental condition, MI-D was able to inhibit cell adhesion
when it was incubated with the cells for 2h. Analysing the images
of experiments (Figure 4D), we can observe that MI-D treatment
promoted loss of cell spreading, which became round, suggesting
a possible activity of MI-D on cytoskeleton organisation.
These observations were confirmed by morphological and
F-actin analyses. Loss of overall cell shape accompanied by cell
shrinkage, membrane blebbing and chromatin condensation,
besides disturbance of the cytoskeleton organisation, are
often observed on apoptotic cells (Hengartner, 2000). The effects
of MI-D on MEL-85 adhesion on ECM and morphology may be
related to its cytotoxic activity. Although the four different cell
lines showed slightly different sensitivities to MI-D, all of them
responded to MI-D in a very similar way, so that the MEL-85
results on adhesion, morphology and cytoskeleton organisation
probably represent an action of MI-D on human melanoma cell
lines.
MI-D is an uncoupler of mitochondrial phosphorylation
(Cadena et al, 1998), whose effects on membranes have been
recognised (Cadena et al, 2002). Touching on this question, MI-D
is an inhibitory uncoupler (Cadena et al, 1998) and according to
Skulachev (1998) and others (Colombo et al, 2001), in some
instances, an uncoupling action could explain the therapeutic
effect of a drug. This seems true for the antitumour action of
carbonylcyanide-m-chlorophenylhydrazone (CCCP) (Newell and
Tannock, 1989) and other anticancer drugs (Keller et al, 1992). The
induction of apoptosis could be a consequence of the cytotoxic
activity of MI-D, as it is already known that drugs, which affect
mitochondrial metabolism, might facilitate the induction of cell
death and overcome apoptosis resistance in cancer cells (Susin
et al, 1998; Colombo et al, 2001). Moreover, since membrane
proteins are highly dependent on membrane organisation and
fluidity (Lopez and Kosk-Kosika, 1997), the effects of MI-D on
membranes could disturb recognition sites, which are necessary
for adhesion.
In conclusion, MI-D is a potent drug against human melanoma
cells and this is the first study on its effects against these cells, as
well as for a mesoionic compound of the 1,3,4-thiadiazolium class.
Figure 6 Effects of MI-D on F-actin cytoskeleton organisation of MEL-85 cells. (A) Micrographs of MEL-85 control cells ( 600). (B) MEL-85 control cells
at a higher magnification showing details of well-organised F-actin cytoskeleton ( 1450). (C) Micrographs of MEL-85 cells treated with 50mM MI-D
( 600). (D) MEL-85 treated with 50mM MI-D, cells under a higher magnification, depicting disturbances to the organisation of F-actin molecules,
concentrated at the edge of cells with a granular pattern (arrow) ( 1200). MEL-85 cells were treated with MI-D, fixed and labelled with a phalloidin-FITC
conjugate and observed at a confocal fluorescence microscope (Confocal Radiance 2100, Bio-Rad) coupled to a Nikon Eclipse 800 with plan apochromatic
objectives.
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features involved in tumour development, such as adhesion to
ECM components. These results, combined with previous data
(Senff-Ribeiro et al, 2003, 2004) that showed MI-D to be a potent
drug against B16-F10 murine melanoma both in vitro and in vivo,
emphasise that MI-D could be a promising drug for the treatment
and study of melanoma.
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